A Clinical Trial of SIBP-A16 Injection in Healthy Adults

Official title

A Randomized, Double-blind, Placebo/Positive Control Phase Ia Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of SIBP-A16 Injection in Healthy Adults

Overview

This study is a randomized, double-blind, placebo/positive control Phase Ia clinical trial evaluating the safety, tolerability, and pharmacokinetics of SIBP-A16 injection in healthy adults

Detailed description

This study plans to set up 5 queues, with queues 1, 3, 4, and 5 each containing 20 participants in the experimental group and 4 participants in the placebo group. Queue 2 contains 20 participants in the experimental group, 20 participants in the positive control group, and 4 participants in the placebo group. The total number of participants included in the five queues is 140. SIBP-A16 injection and placebo will be administered in four different doses and two different ways of administration. The study adopted a sequential injection design. After completing a 14-day preliminary safety observation of drug administration in the previous group, the Safety Review Committee (SRC) will conduct a preliminary safety assessment. Once the SRC evaluation results are safe (not meeting the dose escalation termination criteria), the next group will be enrolled.

Interventions

• Biological SIBP-A16 injection
  Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.
• Biological Nirsevimab
  Single administration via intramuscular.
• Other SIBP-A16 buffer solution
  Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.

Primary outcome measures

• AE (Adverse Events) [Time frame: From day 1 to day 361 after administration]
• SAE (Serious Adverse Events) [Time frame: From day 1 to day 361 after administration]
• Adverse Event of Special Interest (AESI) [Time frame: From day 1 to day 361 after administration]

Secondary outcome measures (3)

• AUC (Area Under The Plasma Concentration Versus Time Curve) [Time frame: Based on multiple pharmacokinetic blood collection points specified in the protocol]
• Cmax (Peak Plasma Concentration) [Time frame: Based on multiple pharmacokinetic blood collection points specified in the protocol]
• Tmax (Peak Time) [Time frame: Based on multiple pharmacokinetic blood collection points specified in the protocol]

Eligibility criteria

Inclusion criteria

• Healthy individuals aged 18 to 45 on the day of enrollment, regardless of gender.
• Male body weight ≥ 50.0 kg, female body weight ≥ 45.0 kg, BMI between 19.0 and 27.0 kg/m2 (including critical values).
• Screening period physical examination, vital sign examination, 12 lead electrocardiogram, chest X-ray or clinical laboratory examination, and other auxiliary examination results show normal or abnormal without clinical significance as judged by the researcher.
• Individuals who voluntarily participate in clinical trials and sign informed consent forms.
• Individuals are able to communicate well with the researchers and understand and comply with the requirements of this study.

Exclusion criteria

• Known to have a history of serious clinical diseases such as mental system, circulatory system, endocrine system, digestive system, respiratory system, hematological and metabolic abnormalities, or any other diseases that can interfere with the test results.
• Individuals with a history of drug allergies or specific allergies, or individuals with allergies, or those known to be allergic to the components or analogues of this drug.
• During the screening period, individuals with abnormal results from physical examination, laboratory tests and clinical significance were identified by the researchers as having an impact on the evaluation of this trial.
• During the screening period, male individuals with QTcF ≥ 450 milliseconds and female individuals with QTcF ≥ 470 milliseconds on electrocardiogram.
• Individuals who have received monoclonal/polyclonal antibody drugs within 6 months prior to screening.
• Individuals have received immunoglobulin or blood product treatment within 6 months prior to screening.
• Individuals who have received passive immune agents, immunosuppressants, or corticosteroids within the 6 months prior to screening.
• Individuals who experience acute illnesses such as fever ≥ 37.3 ℃ (armpit temperature) and diarrhea within one week before their first medication.
• Individuals experienced symptoms and signs of acute upper respiratory tract infection within 2 weeks prior to the first use of medication.
• Individuals who have received the respiratory syncytial virus (RSV) vaccine in the past.
• Individuals have received any vaccine within 30 days prior to screening.
• Select individuals who have smoked at least 5 cigarettes per day within the first 3 months and those who cannot quit smoking throughout the entire trial period.
• Individuals with an average weekly alcohol consumption of ≥ 14 units within the first 3 months of screening, or those who cannot abstain from alcohol during the trial period.
• Individuals have a history of long-term excessive consumption of tea, coffee, or caffeinated beverages.
• Individuals have used any medication or health supplement within the 14 days prior to screening.
• Individuals with a history of drug abuse/dependence or drug use within the past year prior to screening.
• Screening individuals who have participated in any drug clinical trials and have used the investigational drug within the previous 3 months.
• Individuals with a history of blood donation or significant bleeding within the previous 4 weeks prior to screening, or those planning to donate blood or blood components during the study period.
• Pregnant or lactating women.
• Those who have plans to conceive, donate sperm or eggs, or are unable to voluntarily take effective contraceptive measures during the trial period (including partners).
• Those who have special dietary requirements and cannot follow a reasonable and normal diet.
• The researchers believe that the individuals may have other situations that may affect compliance or be unsuitable to participate in this trial

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Prevention

Study locations

China · 1 center

• Wuhan Jinyintan Hospital — Wuhan

Identifiers

NCT: NCT07106918 · SIBP-A16-I

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗